



A *NOTCH3* homozygous nonsense mutation in familial Sneddon syndrome with pediatric stroke

Elli Katharine Greisenegger^{1,2} · Sara Llufrú³ · Angel Chamorro^{4,5} · Alvaro Cervera⁶ · Adriano Jimenez-Escrig⁷ · Klemens Rappersberger⁸ · Wolfgang Marik⁹ · Stefan Greisenegger² · Elisabeth Stögmänn² · Tamara Kopp¹⁰ · Tim M. Strom^{11,12} · Jörg Henes¹² · Anne Joutel¹³ · Alexander Zimprich²

Received: 6 April 2020 / Revised: 5 June 2020 / Accepted: 13 July 2020
© The Author(s) 2020

Abstract

Sneddon syndrome is a rare disorder affecting small and medium-sized blood vessels that is characterized by the association of livedo reticularis and stroke. We performed whole-exome sequencing (WES) in 2 affected siblings of a consanguineous family with childhood-onset stroke and identified a homozygous nonsense mutation within the epidermal growth factor repeat (EGFr) 19 of *NOTCH3*, p.(Arg735Ter). WES of 6 additional cases with adult-onset stroke revealed 2 patients carrying heterozygous loss-of-function variants in putative *NOTCH3* downstream genes, *ANGPTL4*, and *PALLD*. Our findings suggest that impaired *NOTCH3* signaling is one underlying disease mechanism and that bi-allelic loss-of-function mutation in *NOTCH3* is a cause of familial Sneddon syndrome with pediatric stroke.

Keywords *NOTCH3* · CADASIL · Sneddon syndrome · Homozygous nonsense mutation

Introduction

Sneddon syndrome (SS) is a rare disorder (about 4 patients per million), affecting mainly young and predominately female adults [1,2]. It is characterized by recurrent strokes and livedo reticularis, a violaceous, netlike patterning of the

skin [3]. Skin biopsies often display distinct histopathological findings consisting in sequential stage-specific changes in small to medium-sized arteries at the border between dermis and subcutis such as a possibly short-lived endotheliitis, followed by inflammatory obstruction, subendothelial cell proliferation and fibrosis of the occluded artery and shrinkage

✉ Alexander Zimprich
alexander.zimprich@meduniwien.ac.at

¹ Department of Dermatology and Venereology, University Hospital of St. Pölten, Karl Landsteiner University of Health Sciences, St. Pölten, Austria

² Department of Neurology, Medical University of Vienna, Währinger Gürtel 18-20, 1090 Vienna, Austria

³ Laboratory of Advanced Imaging in Neuroimmunological Diseases, Center of Neuroimmunology, Hospital Clinic Barcelona, IDIBAPS and Universitat de Barcelona, Barcelona, Spain

⁴ Department of Neuroscience, Comprehensive Stroke Center, Hospital Clinic Barcelona, Barcelona, Spain

⁵ Institut d'Investigacions Biomèdiques August Pi I Sunyer (IDIBAPS), Universitat de Barcelona, Barcelona, Spain

⁶ Royal Darwin Hospital, Darwin, NT, Australia

⁷ Department of Neurology, Hospital Ramon Y Cajal, 28034 Madrid, Spain

⁸ Department of Dermatology, Rudolfstiftung Hospital, Vienna, Austria

⁹ Division of Neuroradiology and Musculoskeletal Radiology, Department of Biomedical Imaging and Image-Guided Therapy, Medical University of Vienna, Vienna, Austria

¹⁰ Juvenis Medical Center, 1010 Vienna, Austria

¹¹ Institute of Human Genetics, Technical University Munich, Munich, Germany

¹² Department of Internal Medicine II (Hematology, Oncology, Rheumatology and Clinical Immunology), Centre for Interdisciplinary Clinical Rheumatology and Immunology, Eberhard Karls-University Tuebingen, Tuebingen, Germany

¹³ Institute of Psychiatry and Neurosciences of Paris, INSERM UMR1266, University of Paris, 75014 Paris, France

of the vessel [3–5]. Nevertheless, several cases with SS have also been described showing inconspicuous histopathological results [6]. Apart from cerebrovascular events as the prominent clinical manifestation, the range of associated pathologies varies from migraine and seizures to spontaneous abortion or cardiac and renal involvement [2]. The pathogenesis of SS is still unresolved and a matter of discussion [5]. An association with the occurrence of antiphospholipid antibodies and cofactors is described, although the reported frequencies show a vast range also including cases without any antibodies [7]. One explanatory model proposes that the presence of antiphospholipid antibodies might point towards a thrombotic process causing the disease whereas skin biopsies of antibody negative patients suggest a primary inflammatory process with migration and proliferation of smooth muscle cells leading to the narrowing and occlusion of the vessel [3,8]. Furthermore, it has been suggested that genetic factors also contribute to disease development [9,10]. In 2014, a compound heterozygous mutation in the adenosine deaminase 2 (*ADA2*) gene was identified in a large Portuguese family, who presented with livedo reticularis, stroke during early adulthood, leg ulcerations and intermittent fever [11]. More recently, a homozygous *NOTCH3* nonsense mutation was identified in a patient who exhibited livedo reticularis from birth and childhood-onset cavitating leukoencephalopathy with multiple deep lacunar infarcts, disseminated microbleeds and two saccular aneurysms of middle cerebral arteries [12,13].

NOTCH3 encodes a transmembrane receptor predominantly expressed in mural cells of small blood vessels that plays a critical role in their integrity [14]. Dominant mutations in *NOTCH3* cause CADASIL, a small vessel disease of the brain that manifests in mid-adulthood with leukoencephalopathy and subcortical ischemic events, progressively leading to disability, cognitive decline and premature death (MIM#125,310) [15]. In our study, we performed whole-exome sequencing (WES) in a consanguineous family with SS and 6 additional unrelated patients to analyze the genetic background of this disease.

Methods

Study participants

The diagnosis of SS was made based on the clinical criteria for SS, the occurrence of generalized livedo reticularis and the history of cerebrovascular events.

Sequence analyses

Whole exome data were generated from individuals III:2 and III:3 of family 1 and from the 6 other SS cases. Exomes

were enriched with the SureSelect Human All Exon v6 kit (Agilent Technologies, Santa Clara, USA) and DNA libraries were sequenced on a HiSeq 4000 instrument (2×100 cycles, Illumina, San Diego, USA). The average exome coverages ranged from 115× to 197× and 100% of the *NOTCH3* region was covered with at least 25×. Variants were filtered on the minor allele frequency (MAF < 0.001), which was estimated using the in-house database of the Helmholtz-zentrum (> 20,000 exomes) and confirmed by the Genome Aggregation Database (gnomAD). *NOTCH3*, *PALLD* and *ANGPTL4* sequence variants were confirmed by Sanger sequencing using standard protocols.

Differential gene expression of GSE58368 and GSE55203

To find out differentially expressed genes in Notch3 knock-out (KO) mouse models we analyzed 2 microarray datasets (GSE58368 and GSE55203) derived from the Gene Expression Omnibus (GEO) database (<https://www.ncbi.nlm.nih.gov/gds/>). Using the GEO2R web tool (<https://www.ncbi.nlm.nih.gov/geo/geo2r/>) samples from the same cell type were analyzed comparing either heterozygous vs. homozygous (GSE58368) or homozygous vs. wildtype (GSE55203) mice.

Results

In the present study, we performed WES in 2 patients of a family with SS (Fig. 1a, subject III:2 and III:3). Clinical details of patient III:3 were previously reported [10]. Briefly, of 5 siblings 4 are affected with SS presenting livedo reticularis and a history of early onset stroke in childhood. Brain MRI from subjects III:2 and III:3 showed severe periventricular and subcortical white matter lesions and also multiple microbleeds predominantly in the white matter in sibling III:3 (Fig. 1b and Table 1). Laboratory results of sibling III:3 were negative for antiphospholipid antibodies and thrombophilia in general. No data were available on the antibody profile of the second sibling (III:2). The mother was reported to be healthy and the father, who died from a myocardial infarction at the age of 54, was reported to have had livedo reticularis but no signs of cerebrovascular disease (Fig. 1a). Exome-data analysis revealed in both siblings a large homozygous region of 9 Megabases on chr.19p13., indicating consanguinity. This region harbored only two homozygous variants shared by both siblings. First, a missense variant was detected in the *KANK2* gene p.(Met278Lys), which is not present in any publicly available database. This variant was discarded since mutations in this gene have been associated with a distinct recessive disease characterized by a nephrotic




Fig. 1 Genealogical tree of the mutated family and representative brain MRI of patient III:3 **a** Pedigree of family 1: Unaffected family members are indicated by open symbols; affected members by closed symbols including livedo reticularis and cerebrovascular manifestations; half closed symbol (II:1) indicates partial phenotype of SS, with only livedo reticularis; diagonal bars through symbols

denote deceased individuals. **b** Sanger-Sequence Pherograms showing the *NOTCH3* variant in heterozygous form (II:3) and homozygous form (III:2, III:3). **c** Brain MRI from patient III:3 showing diffuse white matter hyperintensities on fluid-attenuated inversion recovery (FLAIR) images; lacunes on T1 and microbleeds on T2*-weighted images, lesions are depicted by an arrow

syndrome and palmoplantar keratoderma with woolly hair (OMIM*614610). Second, a homozygous nonsense variant was identified in exon 14 of the *NOTCH3* gene, p.(Arg735Ter) (Fig. 1b), which lies in the Epidermal Growth Factor repeat (EGFr) 19 of *NOTCH3*. This variant is predicted to result in a premature stop codon and elicit nonsense-mediated mRNA decay [16]. The variant is present heterozygously in 2 out of 61,000 individuals in the gnomAD database. (<https://gnomad.broadinstitute.org/>). The healthy mother was tested to be heterozygous for the p.(Arg735Ter) variant (Fig. 1c, II:3). No other family member was available for genetic testing either because they lived in another region of the country and were not able to transfer to the clinic for testing or were not interested in participating in the study. Based on the severity of the mutation and the known role of *NOTCH3* in cerebrovascular disease, we believe that this mutation is most probably the cause of the disease in this family. To analyze whether *NOTCH3* loss-of-function (lof) mutations are a more frequent cause for SS, we performed WES in 6 additional unrelated patients (Table 2). We found none of the patients to carry a rare variant (MAF < 0.01) in the *NOTCH3* or in the *ADA2* gene. Moreover, high coverage

sequencing allowed us to also exclude copy number variations in both genes. We next hypothesized that genetic variations in genes involved in the *NOTCH3* pathway might be plausible disease candidates. To explore this possibility, we made use of two microarray datasets of *Notch3* KO mouse models from which RNA expression data of brain microvascular fragments (GSE55203) or brain-derived smooth muscle cells (GSE58368) were deposited. Using the GEO2R tool we searched for genes which were significantly downregulated in KO cells compared to wildtype or heterozygous cells (p value < 0.01), assuming that these genes are likely downstream in the *NOTCH3* signaling pathway. We then intersected these 445 genes with the 85 genes carrying lof variants in our 6 patients. We found two patients with lof variants in putative *NOTCH3* downstream genes. Patient 895 carried a heterozygous nonsense variant in the Palladin (*PALLD*) gene, p.(Arg287Ter) and patient 898 carried a heterozygous frameshift variant in the Angiopoietin-like 4 gene (*ANGPTL4*), p.(Gly313AlafsTer49). Both variants are present heterozygously in the gnomAD database (*PALLD*: 10/277212 alleles, *ANGPTL4*: 57/280350 alleles) (Fig. 2, Table 2).

Table 1 Main clinical and neuroimaging features of family members

Patient (sex, age in years) <i>NOTCH3</i> variant	Livedo reticularis	Age at 1st stroke	Neurological manifestations	Brain MRI	Serology
III:2 (F, 49) p.(Arg735Ter) (homozygous)	Yes His.: n.a	3 months	Small vessel stroke Hemiparesis L; mild cognitive impairment; reduced mobility Syncope, urinary incontinence, pseudobulbar palsy with dysphagia and unmotivated laughing	Diffuse WMH Multiple lacunar infarctions	n.a
III:3 (F, 41) p.(Arg735Ter) (homozygous)	Yes His.: normal	5 years	Small vessel stroke Hemiparesis R, ataxia, mild to moderate memory problems, progressive impairment of mobility, pseudobulbar palsy with dysarthria and unmotivated laughing	Diffuse WMH Multiple lacunar infarctions Microbleeds Normal MR angiography	Anti-phospholipid antibodies negative
II:1 (M, 54+) n.a	Yes His.: n.a	None	None	n.a	n.a
II:2 (F, 72) p.(Arg735Ter) (heterozygous)	No	None	None	n.a	n.a
III:4 (F, 47) n.a	Yes His.:n.a	Childhood	Hemiparesis L since childhood, dysarthria, impaired mobility, memory problems	n.a	n.a
III:5 (M, 33) n.a	Yes His.: n.a	2 years	Hemiparesis R	n.a	n.a

R right side, L left side, WMH white matter hyperintensities, His histology, n.a. not available, + deceased

NOTCH3 complete variant description: *NOTCH3*: g.chr19:15296161G>A (GRCh37/hg19); c.2203C>T (NM_000435.2); p.(Arg735Ter) (rs773299588)

Discussion

Herein, we identified a homozygous nonsense mutation in the *NOTCH3* gene in 2 affected siblings of a consanguineous SS family with pediatric stroke. Remarkably, a *NOTCH3* null mutation was identified in another unrelated patient with similar clinical and MRI features, as well as childhood-onset, originally diagnosed with SS [12,13]. These findings, added to the fact that *NOTCH3* plays a key role in small brain vessels, strongly suggests that loss of *NOTCH3* signaling is one underlying disease mechanism for SS.

Although these three patients with SS and a *NOTCH3* null mutation exhibit clinical and neuroimaging features that share similarities with those observed in CADASIL patients, we believe that this genetic form of SS and CADASIL are two distinct entities. First, stroke events started in these 3 SS patients in childhood whereas they occur in CADASIL patients in adulthood, at a mean age of 49 years [15]. Second, livedo reticularis is absent in CADASIL [15]. Third, CADASIL mutations are dominantly inherited and characteristically lead to the loss or gain of a cysteine residue in one of the EGFs of the extracellular domain of *NOTCH3* [15]. Fourth,

accumulating evidence indicates that CADASIL is not caused by a loss of *NOTCH3* function [17–19], but by a neomorphic effect related to the abnormal vascular accumulation of *NOTCH3* protein and possibly an increased activity of the mutant receptor [20,21]. Interestingly, patients with *NOTCH3* lof mutations like our patient (III:2) and the previous described case [12,13] seem to differ from other SS patients. In addition to the childhood-onset and the more severe disease course, *NOTCH3* lof mutation carriers showed negative serum antibody profiles and no extraneurological manifestations. Thus, one might hypothesize that *NOTCH3* lof mutations lead to a distinct and probably more severe clinical subtype of SS. In an attempt to find other possible contributing genes in SS patients with adult-onset stroke, we searched for lof variants in genes downstream to *NOTCH3*. Hereby, we found 2 patients carrying heterozygous lof variants in the *PALLD* and *ANGPTL4* genes. Interestingly, both genes show connections to vascular biology and stroke. *PALLD*, which is predominantly expressed in arterial smooth muscle cells in the brain (<https://betsholtzlab.org/VascularSingleCells/database.html>), was shown to be involved in the modulation of the actin cytoskeleton and plays a role in vascular remodeling [22,23]. In addition, *PALLD* gene

Table 2 Main clinical and neuroimaging features of the 6 additional patients with SS

Patient (sex, age in years)	Livedo reticularis	Cerebrovascular events (Age at 1st manifestation in years)	Brain MRI	Other manifestations	Serology
893 (F, 48)	Yes His.: n.a	Multiple ischemic strokes (41)	Small vessel stroke, multiple small ischemic lesions	Arthralgia	ACA, LAC, ANAs
894 (M, 54)	Yes His.: pos ⁺	Transient ischemic attacks (47)	Small vessel stroke, multiple small bifrontal WMH	Syncope, arterial embolus of the left foot, myocardial infarction, coronary microvascular disease, cardiac arrhythmia	ACA, anti-B2GPI, PR3-ANCA
895 (F, 63) <i>PALLD</i> p.(Arg287Ter)	Yes His.: n.a	Multiple ischemic strokes with consecutive epilepsy (49)	Small vessel stroke, multiple ischemic lesions, microbleeds, progressive stenosis of the left V2-segment of the vertebral artery	Retinal vasculitis with vascular occlusions, Temporalis artery occlusion, Arthritis of the wrist joints	LAC, ACA, anti-B2GPI, ANAs
896 (F, 62)	Yes His.: pos ⁺⁺	Strokes (L and R hemiparesis) (24)	Small vessel stroke, ischemic lesions	Myocardial infarction, coronary artery disease, sick sinus syndrome, chronic kidney disease, renal insufficiency vasculitis of the toes	ACA, ANAs (intermittent positive)
897 (F, 41)	Yes His: negative	Cerebral vasculitis, migraine attacks (38)	Small vessel stroke, multiple small frontal WMH	Arterial hypertension, syncope, bradycardia fibromyalgia, fatigue, ulcerative colitis	ACA, anti-B2GPI, HLA B27
898 (F, 42) <i>ANGPTL4</i> : p.(Gly313AlafsTer49)	Yes His: negative	Small vessel stroke (39)	Posterior cerebral artery infarction (L); occlusion of the left posterior cerebral artery (P2 segment)	Arterial hypertension, miscarriages	ACA, anti-B2GPI, LAC, Anti-dsDNA and ASMA

F female, M male, His histology n.a. not available, pos⁺ early inflammatory stage, pos⁺⁺ subendothelial proliferation, R right side, L left side, WMH white matter hyperintensities, ACA anti-cardiolipin antibody, anti-B2GPI anti-β-2-glycoprotein 1 antibody, Anti-dsDNA anti-double stranded DNA antibody, ANA anti-nuclear antibody, ASMA anti-smooth muscle actin antibody, ANCA anti-neutrophil cytoplasmic antibody, LAC lupus anticoagulant
PALLD and *ANGPDL4* complete variant description: *PALLD*: g.chr4: 169433514 C>T (GRCh37/hg19), NM_016081: c. 859C>T p.(Arg287Ter) (rs138149986); *ANGPTL4*: g.chr19: 19:8436302-TG>T (GRCh37/hg19), NM_139314: c.938del: p.(Gly313AlafsTer49) (rs747940485)




Fig. 2 Gene expression profiles GSE58368 and GSE55203 of *Palld* and *Angptl4*. Datasets were downloaded from the Gene Expression Omnibus (GEO) database. Data derived from GSE58368, show *Angptl4* gene expression in brain derived smooth muscle cells from Notch3 heterozygote mice (Notch3 \pm) compared to cells from

Notch3 KO (Notch3 $-/-$) mice. Data derived from GSE55203 show *Palld* gene expression in brain microvascular fragments from Notch3 KO (Notch3 $-/-$) mice compared to those from wild-type (Notch3 $+/+$) mice

polymorphisms were found to be associated with stroke [24]. *ANGPTL4* was found to be involved in angiogenesis and vessel sprouting in a rat stroke model and was also shown to have a vasculoprotective effect in a mouse stroke model [25,26]. However, both variants *PALLD*-Arg287Ter and *ANGPTL4*-Gly313AlafsTer49 are, although rare, present in the general population with 1 in ~14,000 and 1 in ~2500 respectively and thus unlikely to cause SS on their own. Therefore the presented candidate genes must only be regarded as suggestions for follow up studies and caution in interpretation is advised. Alternatively, we suggest that they could increase disease susceptibility, possibly in combination with other genetic and/or environmental factors. However, one limitation of our study is that unfortunately other family members of patients 895 and 898 were lost to follow up and segregation of the variants could therefore not be investigated.

In conclusion, we propose *NOTCH3* null mutations as a genetic cause for SS with childhood-onset stroke. We further suggest that impairment of *NOTCH3* signaling may also contribute to SS pathogenesis in general.

Availability of data and material

All raw data and a complete list of all rare sequence variants (MAF < 0.001) generated by WES are available upon request.

Author contributions EKG and AZ contributed to conception and design of the study. All authors contributed to material preparation, data collection and patient recruitment. EKG, WM, SL, SG, TMS, AJ and AZ analyzed the data. EKG, AJ and AZ wrote the manuscript. All authors read and approved the final manuscript.

Funding Open access funding provided by Medical University of Vienna.

Compliance with ethical standards

Conflicts of interest Nothing to report.

Ethical approval The study-protocol was approved by the local ethics committee (EK1129/2010).

Informed consent All patients gave their written informed consent for genetic analyses.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>.

References

- Bottin L, Frances C, de Zuttere D, Boelle PY, Muresan IP, Alamowitch S (2015) Strokes in Sneddon syndrome without antiphospholipid antibodies. *Ann Neurol* 77(5):817–829. <https://doi.org/10.1002/ana.24382>
- Bersano A, Morbin M, Ciceri E, Bedini G, Berlit P, Herold M, Saccucci S, Fugnanesi V, Nordmeyer H, Farago G, Savoiaro M, Taroni F, Carriero M, Boncoraglio Giorgio B, Perucca L, Caputi L, Parati Eugenio A, Kraemer M (2016) The diagnostic challenge of Divry van Bogaert and Sneddon Syndrome: Report of three cases and literature review. *J Neurol Sci* 364:77–83. <https://doi.org/10.1016/j.jns.2016.03.011>
- Zelger B, Sepp N, Schmid KW, Hintner H, Klein G, Fritsch PO (1992) Life history of cutaneous vascular lesions in Sneddon's syndrome. *Hum Pathol* 23(6):668–675. [https://doi.org/10.1016/0046-8177\(92\)90323-u](https://doi.org/10.1016/0046-8177(92)90323-u)
- Stockhammer G, Felber SR, Zelger B, Sepp N, Birbamer GG, Fritsch PO, Aichner FT (1993) Sneddon's syndrome: diagnosis by skin biopsy and MRI in 17 patients. *Stroke* 24(5):685–690. <https://doi.org/10.1161/01.str.24.5.685>
- Samanta D, Cobb S, Arya K (2019) Sneddon syndrome: a comprehensive overview. *J Stroke Cerebrovasc Dis* 28(8):2098–2108. <https://doi.org/10.1016/j.jstrokecerebrovasdis.2019.05.013>
- Legierse CM, Canninga-Van Dijk MR, Bruijnzeel-Koomen CA, Kuck-Koot VC (2008) Sneddon syndrome and the diagnostic value of skin biopsies—three young patients with intracerebral lesions and livedo racemosa. *Eur J Dermatol* 18(3):322–328. <https://doi.org/10.1684/ejd.2008.0397>
- Caldas CA, de Carvalho JF (2011) Primary antiphospholipid syndrome with and without Sneddon's syndrome. *Rheumatol Int* 31(2):197–200. <https://doi.org/10.1007/s00296-009-1310-z>
- Frances C, Papo T, Wechsler B, Laporte JL, Biousse V, Piette JC (1999) Sneddon syndrome with or without antiphospholipid antibodies. A comparative study in 46 patients. *Medicine (Baltimore)* 78(4):209–219. <https://doi.org/10.1097/00005792-199907000-00001>
- Szmyrka-Kaczmarek M, Daikeler T, Benz D, Koetter I (2005) Familial inflammatory Sneddon's syndrome—case report and review of the literature. *Clin Rheumatol* 24(1):79–82. <https://doi.org/10.1007/s10067-004-0981-9>
- Llufriu S, Cervera A, Capurro S, Chamorro A (2008) Neurological picture. Familial Sneddon's syndrome with microbleeds in MRI. *J Neurol Neurosurg Psychiatry* 79(8):962. <https://doi.org/10.1136/jnnp.2007.131912>
- Bras J, Guerreiro R, Santo GC (2014) Mutant ADA2 in vasculopathies. *The New England journal of medicine* 371(5):478–480. <https://doi.org/10.1056/NEJMc1405506>
- Pippucci T, Maresca A, Magini P, Cenacchi G, Donadio V, Palombo F, Papa V, Incensi A, Gasparre G, Valentino ML, Preziuso C, Pisano A, Ragno M, Liguori R, Giordano C, Tonon C, Lodi R, Parmeggiani A, Carelli V, Seri M (2015) Homozygous NOTCH3 null mutation and impaired NOTCH3 signaling in recessive early-onset arteriopathy and cavitating leukoencephalopathy. *EMBO Mol Med* 7(6):848–858. <https://doi.org/10.15252/emmm.201404399>
- Parmeggiani A, Posar A, De Giorgi LB, Sangiorgi S, Mochi M, Monari L, Patrizi A, Rossi PG (2000) Sneddon syndrome, arylsulfatase A pseudodeficiency and impairment of cerebral white matter. *Brain Dev* 22(6):390–393
- Domenga V, Fardoux P, Lacombe P, Monet M, Maciazek J, Krebs LT, Klonjkowski B, Berrou E, Mericskay M, Li Z, Tournier-Lasserre E, Gridley T, Joutel A (2004) Notch3 is required for arterial identity and maturation of vascular smooth muscle cells. *Genes Dev* 18(22):2730–2735. <https://doi.org/10.1101/gad.308904>
- Chabriat H, Joutel A, Dichgans M, Tournier-Lasserre E, Boussier MG (2009) Cadasil. *The Lancet Neurology* 8(7):643–653. [https://doi.org/10.1016/S1474-4422\(09\)70127-9](https://doi.org/10.1016/S1474-4422(09)70127-9)
- Maquat LE (2004) Nonsense-mediated mRNA decay: splicing, translation and mRNP dynamics. *Nat Rev Mol Cell Biol* 5(2):89–99. <https://doi.org/10.1038/nrm1310>
- Cognat E, Baron-Menguy C, Domenga-Denier V, Cleophax S, Fouillade C, Monet-Lepretre M, Dewerchin M, Joutel A (2014) Archetypal Arg169Cys mutation in NOTCH3 does not drive the pathogenesis in cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy via a loss-of-function mechanism. *Stroke* 45(3):842–849. <https://doi.org/10.1161/STROKEAHA.113.003339>
- Joutel A (2013) Loss-of-function mutation in the NOTCH3 gene: simply a polymorphism? *Hum Mutat* 34(11):v. <https://doi.org/10.1002/humu.22198>
- Rutten JW, Boon EM, Liem MK, Dauwerse JG, Pont MJ, Vollebregt E, Maat-Kievit AJ, Ginjaar HB, Lakeman P, van Duinen SG, Terwindt GM, Lesnik Oberstein SA (2013) Hypomorphic NOTCH3 alleles do not cause CADASIL in humans. *Hum Mutat* 34(11):1486–1489. <https://doi.org/10.1002/humu.22432>
- Baron-Menguy C, Domenga-Denier V, Ghezali L, Faraci FM, Joutel A (2017) Increased Notch3 activity mediates pathological changes in structure of cerebral arteries. *Hypertension* 69(1):60–70. <https://doi.org/10.1161/HYPERTENSIONAHA.116.08015>
- Neves KB, Harvey AP, Moreton F, Montezano AC, Rios FJ, Alves-Lopes R, Nguyen Dinh Cat A, Rocchiccioli P, Delles C, Joutel A, Muir K, Touyz RM (2019) ER stress and Rho kinase activation underlie the vasculopathy of CADASIL. *JCI Insight*. <https://doi.org/10.1172/jci.insight.131344>
- Liu SQ (1999) Biomechanical basis of vascular tissue engineering. *Crit Rev Biomed Eng* 27(1–2):75–148
- Vanlandewijck M, He L, Mae MA, Andrae J, Ando K, Del Gaudio F, Nahar K, Lebouvier T, Lavina B, Gouveia L, Sun Y, Raschperger E, Rasanen M, Zarb Y, Mochizuki N, Keller A, Lendahl U, Betsholtz C (2018) A molecular atlas of cell types and zonation in the brain vasculature. *Nature* 554(7693):475–480. <https://doi.org/10.1038/nature25739>
- Morrison AC, Bare LA, Luke MM, Pankow JS, Mosley TH, Devlin JJ, Willerson JT, Boerwinkle E (2008) Single nucleotide polymorphisms associated with coronary heart disease predict incident ischemic stroke in the atherosclerosis risk in communities study. *Cerebrovasc Dis* 26(4):420–424. <https://doi.org/10.1159/000155637>
- Buga AM, Margaritescu C, Scholz CJ, Radu E, Zelenak C, Popa-Wagner A (2014) Transcriptomics of post-stroke angiogenesis in the aged brain. *Front Aging Neurosci* 6:44. <https://doi.org/10.3389/fnagi.2014.00044>
- Bouletti C, Mathivet T, Coqueran B, Serfaty JM, Lesage M, Bertrand E, Ardidie-Robouant C, Kauffenstein G, Henrion D, Lapergue B, Mazighi M, Duyckaerts C, Thurston G, Valenzuela DM, Murphy AJ, Yancopoulos GD, Monnot C, Margaill I, Germain S (2013) Protective effects of angiopoietin-like 4 on cerebrovascular and functional damages in ischaemic stroke. *Eur Heart J* 34(47):3657–3668. <https://doi.org/10.1093/eurheartj/eh153>